SCHEMBL4089767

SCHEMBL4089767

CC(=O)N1CCN(c2nc(-c3ccc(F)cc3F)nc3ccccc23)CC1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 4/20 0.60
HIF1A Q16665 2/20 0.57
MAPT P10636 3/20 0.53
CHEK2 O96017 2/20 0.52
LMNA P02545 1/20 0.51
CYP1A2 P05177 4/20 0.50
CYP3A4 P08684 4/20 0.50
NCF1 P14598 2/20 0.50
TSHR P16473 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
SMAD3 P84022 1/20 0.49
CYP2D6 P10635 3/20 0.47
ALDH1A1 P00352 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MAPK1 P28482 2/20 0.47
USP2 O75604 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
ABCB1 P08183 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4090816 0.89 HIF1A (0.68) GBA1HIF1AMAPTLMNACYP1A2
SCHEMBL4095069 0.87 MEN1 (0.63) GBA1HIF1AMAPTCHEK2LMNA
SCHEMBL4090769 0.85 CYP3A4 (0.67) GBA1HIF1AMAPTLMNACYP1A2
SCHEMBL4090989 0.85 HIF1A (0.76) HIF1AMAPTCHEK2LMNACYP1A2
SCHEMBL4085263 0.84 HIF1A (0.79) HIF1AMAPTCHEK2LMNACYP1A2
SCHEMBL4097902 0.84 GBA1 (0.61) GBA1MAPTCYP1A2CYP3A4NCF1
SCHEMBL1084633 0.82 MEN1 (0.56) GBA1HIF1AMAPTCHEK2CYP1A2
SCHEMBL4095774 0.82 GBA1 (0.61) GBA1MAPTCYP1A2CYP3A4NCF1
SCHEMBL4085201 0.81 ABCB1 (0.53) GBA1HIF1AMAPTCYP1A2CYP3A4
SCHEMBL5804844 0.81 CYP1A2 (0.63) GBA1HIF1AMAPTCHEK2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 GBA1 2059/4885HIF1A 1496/4885MAPT 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.